Molecular Insight Pharmaceuticals of Cambridge, MA, has initiated a phase II clinical trial of Azedra, a small-molecule targeted radiotherapeutic agent for the treatment of children with neuroblastoma, the company said.
The objective of the trial is to determine the maximum tolerated dose of Azedra in children. The trial is being coordinated by the New Approaches to Neuroblastoma Therapy (NANT) Consortium.
During the trial, approximately 24 patients across NANT's 14 member sites will be scanned using an imaging dose of Azedra to determine if the imaging dose demonstrates normal biodistribution and tumor uptake of meta-iodobenzylguanidine (MIBG).
Azedra is made of I-131 MIBG molecule radiolabeled with Molecular Insight's Ultratrace technology, which removes unnecessary nonradioactive molecules, according to the firm.
Related Reading
Molecular Insight raises $150 million, November 12, 2007
Molecular Insight completes phase I Azedra trial, October 18, 2007
Molecular Insight buys manufacturing site, October 3, 2007
Molecular Insight appoints CFO, August 16, 2007
Molecular Insight posts Q2 2007 results, August 13, 2007
Copyright © 2008 AuntMinnie.com
